Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-810 (molindone) in children with ADHD and conduct problems
NCT00626236Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Oct 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of molindone in attention deficit hyperactivity disorder (ADHD), conduct disorder (CD), sponsored by Supernus Pharmaceuticals, Inc.. Started Oct 2008; status: completed.
02
Drugs
molindone
03
Conditions
attention deficit hyperactivity disorder (ADHD)conduct disorder (CD)
Beyond the preview
Go deeper on NCT00626236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626236.